NCT05845723View on ClinicalTrials.gov

Tocilizumab and Tofacitinib in the Treatment of Vascular Behçet's Syndrome

PHASE2RecruitingINTERVENTIONAL
Enrollment

81

Participants

Timeline

Start Date

June 1, 2023

Primary Completion Date

June 1, 2026

Study Completion Date

June 1, 2027

Conditions
AneurysmBehcet Syndrome, Vascular Type
Interventions
DRUG

tocilizumab

Participants will receive intravenous infusion of tocilizumab 8mg/kg every 4 weeks for 24 weeks.

DRUG

tofacitinib

Participants will receive tofacitinib 5mg twice a day for 24 weeks of treatment.

DRUG

cyclophosphamide

Participants will receive intravenous infusion of cyclophosphamide 0.5g biweekly for 24 weeks.

Trial Locations (1)

100730

RECRUITING

Peking Union Medical College Hospital, Beijing

All Listed Sponsors
lead

Peking Union Medical College Hospital

OTHER